What happened with MCK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
McKesson buys medicines from manufacturers and distributes them to pharmacies, hospitals and other healthcare providers in the United States and Canada. These customers pay it for the products they buy, and North American pharmaceutical distribution accounts for most revenue. Some manufacturers also compensate McKesson under distribution agreements. Under certain agreements, it benefits when manufacturers raise drug prices and it sells inventory bought earlier at the higher prices, so part of its earnings depends on manufacturer pricing and available inventory.
Beyond wholesale distribution, McKesson supplies specialty medicines and helps community cancer and other specialty practices run their businesses, including through The U.S. Oncology Network. It also sells technology and logistics services that help biopharma companies and healthcare organizations get prescriptions authorized and medicines to patients. Its medical-surgical business supplies products and services to settings such as physician offices and home care; McKesson plans to separate that business into an independent company.
Revenue depends heavily on a small group of large customers, with CVS Health its largest customer and a major pharmaceutical distribution partner. Purchasing is also concentrated among a small group of suppliers. McKesson must maintain regulatory approvals and meet drug-storage, security and distribution requirements to operate. Court consent decrees also govern parts of its controlled-substance distribution.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cencora vies with McKesson for pharmacies and health systems that buy drugs and related services from them. Its business supplying medicines and services to community oncologists and retina specialists is also a direct point of competition for McKesson’s specialty business.
Cardinal Health competes with McKesson for drug purchases, services for specialty practices and medical-surgical supply orders from healthcare providers. Its Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution results show how these competing businesses are performing.
McKesson depends heavily on CVS Health’s drug purchases: CVS, which operates retail pharmacies, accounted for approximately 24% of McKesson’s consolidated revenue in fiscal 2026. Their pharmaceutical distribution partnership runs through June 2027, making news about its renewal especially important for McKesson holders.
Eli Lilly supplies medicines that McKesson distributes, so expanding use of Lilly’s Mounjaro and Zepbound increases demand for McKesson’s drug distribution. Use of those two medicines is the part of Lilly’s business to watch for this connection.
Medline Inc. competes with McKesson for contracts supplying medical-surgical products to surgery centers, physician offices and post-acute facilities. Watch its agreements to serve as these providers’ main supplier—the Prime Vendor contracts that put the two companies head-to-head.
Henry Schein competes with McKesson for medical supplies and equipment orders from physician practices, surgery centers and other alternate-care providers. Its sales to these customers, rather than its dental business, are the relevant competitive read for McKesson.
Eli Lilly & Co. earningsLLY
Eli Lilly’s report will show whether use of Mounjaro and Zepbound is adding demand for McKesson’s drug distribution.
Watch Lilly’s disclosures on use of Mounjaro and Zepbound. Greater use points to more demand for McKesson to distribute these medicines; slower use points to less support from them. This is a read on distribution demand from these two drugs, not a verdict on McKesson’s total drug sales.
McKesson Corporation earningsThis company
McKesson’s report will show whether added North American drug-distribution sales are turning into more operating profit.
Compare North American Pharmaceutical revenue with its operating profit. If profit grows faster than revenue, the added sales are generating enough profit to outpace the costs of distributing them. If revenue rises but profit lags, McKesson is moving more drugs without improving the profit earned on those sales. The question is whether its core distribution growth is becoming more profitable.
Cencora, Inc. earningsCOR
Cencora’s report will show how its medicine and service business with community oncologists and retina specialists is faring, where it competes with McKesson.
Look at how Cencora’s medicine and service business with community oncologists and retina specialists performs. Strength would show it gaining momentum among specialty customers McKesson also serves; weakness would point to less competitive momentum in those channels. The takeaway is the pressure facing McKesson’s specialty business, not McKesson’s own results.
CVS HEALTH CORPORATION earningsCVS
CVS Health’s report will show how its retail pharmacy business is doing; it accounted for about 24% of McKesson’s fiscal 2026 revenue.
Watch CVS’s retail pharmacy business and any indication that its drug purchasing is strengthening or weakening. Steady pharmacy activity and supported purchasing would show a sound demand base at McKesson’s major customer; weakness or pressure on purchases would put this important revenue stream at risk. Their distribution partnership runs through June 2027, but this report cannot establish whether it will be renewed.
Medline Inc. earningsMDLN
Medline Inc.’s report will show how it is competing for medical-surgical supply orders from providers that also buy from McKesson.
Watch Medline’s Prime Vendor contract activity and its business serving surgery centers, physician offices and post-acute providers. More contract wins or stronger activity would show it gaining ground with customers McKesson also serves; setbacks or weaker activity would point to less competitive pressure in that channel. The takeaway is the competition facing McKesson’s medical-surgical business, not that Medline’s overall results directly measure McKesson’s sales.
